Patents Assigned to National Cerebral and Cardiovascular Center
  • Publication number: 20220401043
    Abstract: A cerebral infarction treatment support system (100) includes a detection device (10), a display (30), and an image controller (20), and the image controller (20) includes a receiver (21) configured to receive at least one of first information (41) generated by the detection device (10) or second information (42) related to a susceptibility gene generated based on the first information (41), and a video output (22) configured to output at least one of the received first information (41) or second information (42) to the display (30).
    Type: Application
    Filed: October 28, 2020
    Publication date: December 22, 2022
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, SHIMADZU CORPORATION
    Inventors: Masafumi IHARA, Takeshi YOSHIMOTO, Daisuke KAWAKAMI
  • Publication number: 20220370510
    Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.
    Type: Application
    Filed: July 29, 2022
    Publication date: November 24, 2022
    Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.
    Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
  • Patent number: 11464441
    Abstract: A myocardial excitation complementation/visualization apparatus includes an acquiring section that acquires intracardiac electrocardiograms of a subject, the intracardiac electrocardiograms being recorded by a recording unit having a plurality of electrodes, a processing section that performs a computation for completing and visualizing a state of excitation in a myocardium of the subject based on the intracardiac electrocardiograms, and a displaying section that displays the state of excitation in the myocardium of the subject based on an output of the processing section. The processing section includes a first generating section, a correcting section, a second generating section, and a third generating section. The displaying section displays a change of the state of excitation in the myocardium of the subject based on the visualized data.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: October 11, 2022
    Assignees: SHIGA UNIVERSITY OF MEDICAL SCIENCE, NIHON KOHDEN CORPORATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Takashi Ashihara, Koji Takizawa, Tatsuo Nishihara, Nobuhiro Suzuki, Yuuho Iwanaga, Akio Ota, Takeshi Tsuchiya, Kazuo Nakazawa, Shin Inada
  • Publication number: 20220265603
    Abstract: The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 25, 2022
    Applicants: NATIONAL HOSPITAL ORGANIZATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Advanced Innovation Development Co., Ltd., FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
    Inventors: Noriko ASAHARA, Takayuki INOUE, Masashi TANAKA, Masafumi IHARA, Satoshi SAITO
  • Publication number: 20220226512
    Abstract: Composite particles, each of which is obtained by forming, on the surface of a gadolinium oxide-containing particle, a cover film that contains a polymer obtained by polymerizing a monomer component containing a monomer having an ethylenically unsaturated bond; a macrophage imaging agent which contains the composite particles; and a method for producing composite particles, wherein a monomer component containing a monomer having an ethylenically unsaturated bond and gadolinium oxide-containing particles are mixed with each other, and after emulsifying the thus-obtained monomer component-containing mixture in water in the presence of a surfactant and a polymerization initiator in water, the monomer component is polymerized, thereby forming cover films on the surfaces of the gadolinium oxide-containing particles.
    Type: Application
    Filed: May 27, 2020
    Publication date: July 21, 2022
    Applicants: KYOTO UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JSR CORPORATION
    Inventors: Teruyuki KONDO, Yu KIMURA, Aoi SON, Tetsuya MATSUDA, Hirohiko IMAI, Hirokazu KOSEKI, Tomohiro AOKI, Katsuyuki TAKASE, Masaaki MIYAJI, Koji TAMORI, Takeaki MASUDA, Hirokazu KAI
  • Patent number: 11389486
    Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: July 19, 2022
    Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATION
    Inventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
  • Publication number: 20220196681
    Abstract: The present invention is intended to provide a novel biomarker for detecting arteriosclerosis-related disease or for evaluating the stage of progression of arteriosclerosis, and specifically, the present invention relates to a marker for detecting arteriosclerosis-related disease or for evaluating the stage of progression of arteriosclerosis, comprising an NPC2 (Niemann-Pick disease type C2) protein and/or an IGFBP7 (Insulin-like growth factor-binding protein 7) protein.
    Type: Application
    Filed: March 29, 2019
    Publication date: June 23, 2022
    Applicants: Eiken Kagaku Kabushiki Kaisha, National Cerebral and Cardiovascular Center
    Inventors: Naoto MINAMINO, Hiroaki YAGI, Mitsuhiro NISHIGORI, Hatsue UEDA, Hitoshi MATSUDA, Yusuke MURAKAMI
  • Publication number: 20220178945
    Abstract: The present invention is intended to provide a novel biomarker capable of detecting aortic aneurysm with high sensitivity, and specifically, the present invention relates to a detection marker of aortic aneurysm, comprising an NPC2 (Niemann-Pick disease type C2) protein and/or an IGFBP7 (Insulin-like growth factor-binding protein 7) protein.
    Type: Application
    Filed: March 29, 2019
    Publication date: June 9, 2022
    Applicants: EIKEN KAGAKU KABUSHIKI KAISHA, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Naoto MINAMINO, Hiroaki YAGI, Mitsuhiro NISHIGORI, Hatsue UEDA, Hitoshi MATSUDA, Yusuke MURAKAMI
  • Patent number: 11273222
    Abstract: Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4? and 2? positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: March 15, 2022
    Assignee: National Cerebral and Cardiovascular Center
    Inventors: Mariko Harada-Shiba, Fumito Wada, Satoshi Obika, Tsuyoshi Yamamoto, Keisuke Tachibana, Tadayuki Kobayashi, Kosuke Ito, Motoki Sawamura
  • Patent number: 11253626
    Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 22, 2022
    Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JMS CO., LTD.
    Inventors: Tetsuji Yamaoka, Maria Chiara Munisso, Atsushi Mahara, Takashi Yamamoto
  • Publication number: 20220000949
    Abstract: An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 6, 2022
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Kenji KANGAWA, Takashi NOJIRI, Motofumi KUMAZOE, Yasutake TANAKA, Yoshiyuki SHISHIDO, Takashi ASAHARA, Takahito MIURA, Keisuke TANIGUCHI
  • Publication number: 20210395688
    Abstract: The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises a preparation step of preparing, on a culturing surface of a cell culture container, a first coated region coated with a temperature-responsive polymer and/or a temperature-responsive polymer composition, and a plurality of second coated regions located at an edge of the first coated region and coated with a cell adhesive substance; and a seeding and culturing step of seeding cells in the first coated region and the second coated regions and culturing the cells to produce a cell structure.
    Type: Application
    Filed: September 7, 2021
    Publication date: December 23, 2021
    Applicant: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Yasuhide NAKAYAMA, Ryosuke IWAI, Yasushi NEMOTO
  • Publication number: 20210395687
    Abstract: The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises producing a coated region in which a culturing surface is coated with a temperature-responsive polymer or a temperature-responsive polymer composition, forming a droplet of a cell suspension in the coated region, and performing cell culturing in the droplet. A surface zeta potential of the coated region is 0 mV to 50 mV.
    Type: Application
    Filed: September 7, 2021
    Publication date: December 23, 2021
    Applicant: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Yasuhide NAKAYAMA, Ryosuke IWAI, Yasushi NEMOTO
  • Patent number: 11149252
    Abstract: The present disclosure aims to provide a method of efficiently manufacturing a cell mass, a cell structure, or a three-dimensional tissue body using a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition. The manufacturing method of a cell mass, a cell structure, or a three-dimensional tissue body of the present disclosure includes seeding and culturing cells on a culturing surface coated with a temperature-responsive polymer or a temperature-responsive polymer composition.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: October 19, 2021
    Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Yasuhide Nakayama, Ryosuke Iwai, Yasushi Nemoto
  • Publication number: 20210100790
    Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 8, 2021
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
    Inventors: Tadamasa MATSUMOTO, Masafumi IHARA, Satoshi SAITO, Masanori FUKUSHIMA
  • Patent number: 10898098
    Abstract: A myocardial excitation determining apparatus which can support the determination of excitation dynamics of the myocardium during atrial fibrillation is provided. A myocardial excitation determining apparatus has: an acquiring section 2 which acquires an intracardiac electrocardiogram of a subject; a processing section 3 which computes to produce visualized data indicating a state of excitation in the myocardium, based on the intracardiac electrocardiogram; and a determining section 4 which determines the type of excitation dynamics of the myocardium based on the visualized data.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: January 26, 2021
    Assignees: SHIGA UNIVERSITY OF MEDICAL SCIENCE, NIHON KOHDEN CORPORATION, Takeshi TSUCHIYA, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Takashi Ashihara, Koji Takizawa, Tatsuo Nishihara, Nobuhiro Suzuki, Yuuho Iwanaga, Akio Ota, Takeshi Tsuchiya, Kazuo Nakazawa, Shin Inada
  • Publication number: 20200305731
    Abstract: Provided is a cerebral blood flow measurement method of quantitatively measuring cerebral blood flow, the measurement method including: a tracer introducing step of introducing a tracer into a blood vessel; a light applying step of applying measurement light including an absorption wavelength of the tracer to a head; a light detecting step of detecting the measurement light propagating in the head and generating a detection signal based on light intensity of the measurement light; and a calculation step of calculating cerebral blood flow on the basis of a relative change over time ?Q of a concentration of the tracer in a brain tissue which is acquired on the basis of the detection signal and a predetermined relationship between a change over time of a concentration Pa of the tracer in an artery of the head and cerebral blood flow.
    Type: Application
    Filed: October 24, 2018
    Publication date: October 1, 2020
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, HAMAMATSU PHOTONICS K.K.
    Inventors: Kenji YOSHITANI, Shinya KATO, Mariko EZAKA, Takeo OZAKI
  • Publication number: 20200197446
    Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.
    Type: Application
    Filed: June 20, 2018
    Publication date: June 25, 2020
    Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.
    Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
  • Publication number: 20200190590
    Abstract: Provided is a method for predicting probability of ischemic stroke onset. A method for predicting a risk of ischemic stroke onset, the method comprising: a detection step of detecting presence or absence of a RNF213 p.R4810K gene variant in a sample derived from a test subject who does not develop ischemic stroke; and a determination step of determining whether a probability of ischemic stroke onset of the test subject is high or not, based on the presence or absence of the RNF213 p.R4810K gene variant in the detection step, and gender information of the test subject. A genetic marker for predicting a risk of ischemic stroke onset using gender information, comprising a RNF213 p.R4810K gene variant. A biomarker for predicting a risk of ischemic stroke onset using gender information, comprising a polypeptide encoded by a RNF213 p.R4810K gene variant.
    Type: Application
    Filed: December 10, 2019
    Publication date: June 18, 2020
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, SHIMADZU CORPORATION
    Inventors: Masafumi IHARA, Shuhei OKAZAKI, Daisuke KAWAKAMI
  • Patent number: 10624555
    Abstract: A myocardial excitation complementation/visualization apparatus includes an acquiring section that acquires intracardiac electrocardiograms of a subject, the intracardiac electrocardiograms being recorded by a recording unit having a plurality of electrodes, a processing section that performs a computation for completing and visualizing a state of excitation in a myocardium of the subject based on the intracardiac electrocardiograms, and a displaying section that displays the state of excitation in the myocardium of the subject based on an output of the processing section. The processing section includes a first generating section, a correcting section, a second generating section, and a third generating section. The displaying section displays a change of the state of excitation in the myocardium of the subject based on the visualized data.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 21, 2020
    Assignees: SHIGA UNIVERSITY OF MEDICAL SCIENCE, NIHON KOHDEN CORPORATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
    Inventors: Takashi Ashihara, Koji Takizawa, Tatsuo Nishihara, Nobuhiro Suzuki, Yuuho Iwanaga, Akio Ota, Takeshi Tsuchiya, Kazuo Nakazawa, Shin Inada